Novo makes fresh obesity play with $2.2bn Septerna deal

The World's Obesity Problem Continues to Grow

"Obesity in the US could exceed 40% of all adults by 2030..."

In a new strategic movement that consolidates its leadership in the obesity market, Novo Nordisk has announced an agreement for $2.2 billion with the biotechnology company Septerna, based in San Francisco, for the development of anti-obesity pills. According to the original report, this agreement reflects the efforts of the Danish pharmaceutical company to remain a benchmark in this highly competitive market. Through this exclusive collaboration…

Novo makes fresh obesity play with $2.2bn Septerna deal

A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity

Novo to work with Septerna in hunt for oral obesity drugs

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the latest deal Novo has struck to expand its obesity pipeline.

Novo Nordisk (NOVO B) Balance Sheet & Financial Health Metrics - Simply Wall St

Discover Novo Nordisk's balance sheet and financial health metrics. From total debt, total equity, assets to cash-on-hand, interest coverage and more.

The prevalence of child obesity increased by 1.6% between 2019 and 2022